How Are the Responsibilities of the Authorized Representative Divided for Overseas Registration of IVD Products?

In overseas registration of IVD products, the Authorized Representative (AR) acts as the manufacturer's legal agent in the target market, bearing compliance responsibilities such as product registration, post-market surveillance, adverse event reporting, and product recall. The division of AR responsibilities depends on the regulatory requirements of the target country/region, for example, EU MDR (IVDR), US FDA (not mandatory but commonly designated), China NMPA, Japan PMDA, Saudi SFDA, Thailand FDA, etc. Manufacturers must first determine whether the product falls under the medical device regulatory scope of the target country, then determine the registration pathway based on risk classification (e.g., EU Class A/B/C/D, China Class III, etc.). Existing NMPA, CE, FDA, ISO 13485, or MDSAP documentation may be partially reused, but technical files, performance validation, risk management reports, clinical evaluation (or literature review), and labeling must comply with local language and regulatory formats. The AR is responsible for communication with regulatory authorities, maintaining technical documents, and assisting with post-market surveillance, and its legal liability is often joint with the manufacturer. Common risks include: registration delays due to insufficient AR capability; unclear control of certificates affecting changes and renewals; and penalties from neglected post-market surveillance responsibilities. Manufacturers should assess agent qualifications in advance, clarify contract terms, and establish a localized document conversion process.

Applicable Scenarios and Core Issues

Overseas registration of IVD products involves regulatory systems in multiple countries or regions, and the division of AR responsibilities directly impacts registration efficiency and compliance risk. When entering markets such as the EU, Middle East, Southeast Asia, and Latin America, manufacturers must clearly define the statutory role of the AR: it is not limited to submitting registration applications but also includes ongoing responsibilities such as post-market surveillance, adverse event reporting, and product recall coordination. Core issues include: who appoints the AR (manufacturer or distributor); whether the scope of authorization covers all product models; how certificate control is transferred upon contract termination; and whether the same AR can be used for multiple country registrations. Actual cases show that some manufacturers have had registered products cancelled due to unclear AR change clauses.

For example, under the EU IVDR, the AR must be a legal entity registered in the EU and is responsible for PRRC contact, technical document retention, and vigilance system reporting. In Japan, the MAH (Marketing Authorization Holder) performs similar functions but must be a local legal entity. Manufacturers need to distinguish the legal differences between "registration applicant" and "authorized representative": the former is the nominal holder of the registration certificate, while the latter is the day-to-day compliance contact. Confusing the two may lead to a broken chain of responsibility.

Registration Decision Logic

Manufacturers should first confirm the product's intended use, mechanism of action, usage scenario, contact with the human body, duration of use, sterility status, energy source, software content, or IVD attributes, then determine risk classification and submission pathway. An incorrect pathway judgment can lead to misdirection in subsequent translation, notarization, authorization, testing, and supplementary data.

For target market projects, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who communicates with regulators, who handles import and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are only vaguely addressed in commercial contracts, market control may be compromised later.

Documents and Evidence

Common documents include product description, model/specification matrix, intended use, risk classification justification, ISO 13485 or applicable quality system certification, technical file, performance validation report, risk management file, clinical evaluation or clinical evidence, labeling, authorization documents, existing registration certificates, manufacturer's declaration, and post-market surveillance documentation.

The key to document quality is consistency, not quantity. Label claims, test report coverage, clinical evidence scope, risk management conclusions, label warnings, and registration application information must all support each other. Regulators focus on whether the product is safe, effective, and traceable for its intended use, not on the number of files uploaded.

Common Mistakes

• Treating the registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.
• Translating domestic NMPA documentation directly and submitting it without rearranging evidence according to the target market pathway.
• Having too many models/specifications but insufficient test report, clinical evidence, or label coverage.
• Selecting a local agent solely based on sales cooperation without clearly defining regulatory responsibilities, certificate control, and post-market maintenance obligations.
• Inconsistencies among labels, instructions for use, promotional materials, and registration documents, leading to supplement requests or post-market compliance risks.
• Failing to plan for cross-country document reuse, resulting in repeated effort for each country and increased cost and timelines.

Manufacturer Preparation Checklist

Before starting the project, manufacturers are advised to use an internal checklist to confirm the document baseline and avoid discovering key evidence gaps after submission.

• Compile target product list, model/specification matrix, and intended use descriptions.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English labeling.
• Confirm the local agent's or AR's responsibilities, fees, certificate control, and exit mechanism.
• Establish a target country gap assessment table, clearly identifying items requiring additional testing, translation, notarization, or supplemental declarations.

AIMEILI Regulatory Interpretation and Business Impact

AIMEILI recommends that manufacturers not view target market registration as a one-time document submission but manage it as an overseas market access project. For companies planning to enter multiple countries, first establishing a clear set of core technical documents and evidence matrices, then converting them according to national requirements, is typically faster and more stable than preparing documents country by country, and also facilitates subsequent changes and renewals.

From a project management perspective, manufacturers should prioritize controlling three things: first, product classification and pathway determination; second, consistency of the document evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even with extensive documentation, projects may encounter repeated supplement requests, agent communication issues, and post-market maintenance difficulties.

Frequently Asked Questions

Can documents from the target market registration directly use domestic materials? Domestic documents can serve as a basis but generally cannot be submitted as-is. Manufacturers need to adjust the document structure, language, labeling, authorization files, and evidence chain according to local regulatory requirements.

When is the best time to initiate a gap assessment? It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange for supplementary testing, translation, label adjustments, and agent selection.

Why does local agent selection affect registration quality? Local agents are typically involved in registration communication, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control and market stability.

Project Execution Recommendations

When executing such registration projects, manufacturers should establish a project ledger that tracks product list, models/specifications, registration pathway, document responsible person, translation status, testing status, local agent communication records, and expected submission date in a single table. This helps identify document gaps in time and enables management to assess whether the project will affect launch plans.

For companies with existing registration bases in multiple countries, an evidence reuse matrix should also be established, clearly indicating which documents can serve as core evidence and which must be reissued or supplemented per country requirements. Labels, clinical evaluations, risk management, performance validation, and quality system certificates must remain version-consistent.

Key steps: Confirm target market and product list. Complete risk classification and pathway determination. Establish a document gap assessment table. Clarify local agent and certificate control. Track translation, notarization, testing, and supplement status. Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From the regulatory review perspective, quality system documents are not isolated certificates. Regulators typically check whether the manufacturer name, production address, product scope, certificate validity, applicable standards, and technical documents are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the production address, model/specification, and label version are inconsistent with the test report, even if extensive documentation has been prepared, supplement requests may still be issued.

Manufacturers should create an evidence consistency checklist before submission, mapping product name, model/specification, intended use, applicable standards, test report number, clinical evaluation conclusion, risk management version, label version, and quality system certificate item by item. This basic step significantly reduces the likelihood of supplement requests, especially for projects involving multiple GHWP member countries or multiple product families.

Localization Conversion and Agent Responsibility

Target market registration projects typically involve arrangements for local agents, authorized representatives, importers, or registration holders. Manufacturers need to confirm in advance whether the local partner is only responsible for document submission or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and market stability.

Labels and authorization documents cannot simply be translated. Manufacturers should verify local language requirements, product claim boundaries, warnings, storage/transport conditions, UDI or traceability requirements, importer information, AR information, and after-sales contact details. For companies with existing CE, FDA, NMPA, or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than creating a completely new set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mark the end of compliance work. Manufacturers must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall processes, label versions, and regulatory update records. Many companies invest heavily in the certification phase but neglect post-market maintenance. Subsequently, when changes such as production address updates, model expansions, labeling updates, or agent replacements occur, disconnects between certificates and market sales often arise.

AIMEILI recommends incorporating this issue into the annual international registration plan: first clarify target market priorities, then establish a reusable document package and country gap checklist, and finally arrange submission, supplement, post-market maintenance, and renewal milestones. This approach not only improves the efficiency of single-country registrations but also helps companies build a replicable overseas compliance capability, reducing the cost of starting from scratch for each new market.